A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial

BackgroundIntensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of the...

Full description

Bibliographic Details
Main Authors: Staite, Emily, Bayley, Adam, Al-Ozairi, Ebaa, Stewart, Kurtis, Hopkins, David, Rundle, Jennifer, Basudev, Neel, Mohamedali, Zahra, Ismail, Khalida
Format: Article
Language:English
Published: JMIR Publications 2020-07-01
Series:JMIR mHealth and uHealth
Online Access:https://mhealth.jmir.org/2020/7/e15448
id doaj-4d31eff614bb4bd7b7015cbb041d45ef
record_format Article
spelling doaj-4d31eff614bb4bd7b7015cbb041d45ef2021-05-03T04:33:24ZengJMIR PublicationsJMIR mHealth and uHealth2291-52222020-07-0187e1544810.2196/15448A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled TrialStaite, EmilyBayley, AdamAl-Ozairi, EbaaStewart, KurtisHopkins, DavidRundle, JenniferBasudev, NeelMohamedali, ZahraIsmail, Khalida BackgroundIntensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of their effectiveness is limited. ObjectiveThis randomized controlled trial (RCT) aimed to test the feasibility of a web-based diabetes prevention program (DPP) with step-dependent feedback messages versus a standard web-based DPP in people with prediabetes. MethodsWe employed a two-arm, parallel, single-blind RCT for people at high risk of developing diabetes. Patients with a hemoglobin A1c (HbA1c) level of 39-47 mmol/mol were recruited from 21 general practices in London. The intervention integrated a smartphone app delivering a web-based DPP course with SMS texts incorporating motivational interviewing techniques and step-dependent feedback messages delivered via a wearable device over 12 months. The control group received the wearable technology and access to the web-based DDP but not the SMS texts. As this was a feasibility study, the primary aim was to estimate potential sample size at different stages of the study, including the size of the target study population and the proportion of participants who consented, were randomized, and completed follow-up. We also measured the main outcomes for a full-scale RCT, namely, change in weight and physical activity at 6- and 12-month follow-ups, and secondary outcomes, including changes in the HbA1c level, blood pressure, waist circumference, waist-to-hip ratio, and lipid levels. ResultsWe enrolled 200 participants: 98 were randomized to the intervention and 102 were randomized to the control group. The follow-up rate was higher in the control group (87/102, 85.3%) than in the intervention group (69/98, 70%) at 12 months. There was no treatment effect on weight at 6 months (mean difference 0.15; 95% CI −0.93 to 1.23) or 12 months (mean difference 0.07 kg; 95% CI −1.29 to 1.44) or for physical activity levels at 6 months (mean difference −382.90 steps; 95% CI −860.65 to 94.85) or 12 months (mean difference 92.64 steps; 95% CI −380.92 to 566.20). We did not observe a treatment effect on the secondary outcomes measured at the 6-month or 12-month follow-up. For the intervention group, the mean weight was 92.33 (SD 15.67) kg at baseline, 91.34 (SD 16.04) kg at 6 months, and 89.41 (SD 14.93) kg at 12 months. For the control group, the mean weight was 92.59 (SD 17.43) kg at baseline, 91.71 (SD 16.48) kg at 6 months, and 91.10 (SD 15.82) kg at 12 months. In the intervention group, the mean physical activity was 7308.40 (SD 4911.93) steps at baseline, 5008.76 (SD 2733.22) steps at 6 months, and 4814.66 (SD 3419.65) steps at 12 months. In the control group, the mean physical activity was 7599.28 (SD 3881.04) steps at baseline, 6148.83 (SD 3433.77) steps at 6 months, and 5006.30 (SD 3681.1) steps at 12 months. ConclusionsThis study demonstrates that it is feasible to successfully recruit and retain patients in an RCT of a web-based DPP. Trial RegistrationClinicalTrials.gov NCT02919397; http://clinicaltrials.gov/ct2/show/NCT02919397https://mhealth.jmir.org/2020/7/e15448
collection DOAJ
language English
format Article
sources DOAJ
author Staite, Emily
Bayley, Adam
Al-Ozairi, Ebaa
Stewart, Kurtis
Hopkins, David
Rundle, Jennifer
Basudev, Neel
Mohamedali, Zahra
Ismail, Khalida
spellingShingle Staite, Emily
Bayley, Adam
Al-Ozairi, Ebaa
Stewart, Kurtis
Hopkins, David
Rundle, Jennifer
Basudev, Neel
Mohamedali, Zahra
Ismail, Khalida
A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
JMIR mHealth and uHealth
author_facet Staite, Emily
Bayley, Adam
Al-Ozairi, Ebaa
Stewart, Kurtis
Hopkins, David
Rundle, Jennifer
Basudev, Neel
Mohamedali, Zahra
Ismail, Khalida
author_sort Staite, Emily
title A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_short A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_full A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_fullStr A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_full_unstemmed A Wearable Technology Delivering a Web-Based Diabetes Prevention Program to People at High Risk of Type 2 Diabetes: Randomized Controlled Trial
title_sort wearable technology delivering a web-based diabetes prevention program to people at high risk of type 2 diabetes: randomized controlled trial
publisher JMIR Publications
series JMIR mHealth and uHealth
issn 2291-5222
publishDate 2020-07-01
description BackgroundIntensive lifestyle interventions are effective in reducing the risk of type 2 diabetes, but the implementation of learnings from landmark studies is expensive and time consuming. The availability of digital lifestyle interventions is increasing, but evidence of their effectiveness is limited. ObjectiveThis randomized controlled trial (RCT) aimed to test the feasibility of a web-based diabetes prevention program (DPP) with step-dependent feedback messages versus a standard web-based DPP in people with prediabetes. MethodsWe employed a two-arm, parallel, single-blind RCT for people at high risk of developing diabetes. Patients with a hemoglobin A1c (HbA1c) level of 39-47 mmol/mol were recruited from 21 general practices in London. The intervention integrated a smartphone app delivering a web-based DPP course with SMS texts incorporating motivational interviewing techniques and step-dependent feedback messages delivered via a wearable device over 12 months. The control group received the wearable technology and access to the web-based DDP but not the SMS texts. As this was a feasibility study, the primary aim was to estimate potential sample size at different stages of the study, including the size of the target study population and the proportion of participants who consented, were randomized, and completed follow-up. We also measured the main outcomes for a full-scale RCT, namely, change in weight and physical activity at 6- and 12-month follow-ups, and secondary outcomes, including changes in the HbA1c level, blood pressure, waist circumference, waist-to-hip ratio, and lipid levels. ResultsWe enrolled 200 participants: 98 were randomized to the intervention and 102 were randomized to the control group. The follow-up rate was higher in the control group (87/102, 85.3%) than in the intervention group (69/98, 70%) at 12 months. There was no treatment effect on weight at 6 months (mean difference 0.15; 95% CI −0.93 to 1.23) or 12 months (mean difference 0.07 kg; 95% CI −1.29 to 1.44) or for physical activity levels at 6 months (mean difference −382.90 steps; 95% CI −860.65 to 94.85) or 12 months (mean difference 92.64 steps; 95% CI −380.92 to 566.20). We did not observe a treatment effect on the secondary outcomes measured at the 6-month or 12-month follow-up. For the intervention group, the mean weight was 92.33 (SD 15.67) kg at baseline, 91.34 (SD 16.04) kg at 6 months, and 89.41 (SD 14.93) kg at 12 months. For the control group, the mean weight was 92.59 (SD 17.43) kg at baseline, 91.71 (SD 16.48) kg at 6 months, and 91.10 (SD 15.82) kg at 12 months. In the intervention group, the mean physical activity was 7308.40 (SD 4911.93) steps at baseline, 5008.76 (SD 2733.22) steps at 6 months, and 4814.66 (SD 3419.65) steps at 12 months. In the control group, the mean physical activity was 7599.28 (SD 3881.04) steps at baseline, 6148.83 (SD 3433.77) steps at 6 months, and 5006.30 (SD 3681.1) steps at 12 months. ConclusionsThis study demonstrates that it is feasible to successfully recruit and retain patients in an RCT of a web-based DPP. Trial RegistrationClinicalTrials.gov NCT02919397; http://clinicaltrials.gov/ct2/show/NCT02919397
url https://mhealth.jmir.org/2020/7/e15448
work_keys_str_mv AT staiteemily awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT bayleyadam awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT alozairiebaa awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT stewartkurtis awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT hopkinsdavid awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT rundlejennifer awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT basudevneel awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT mohamedalizahra awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT ismailkhalida awearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT staiteemily wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT bayleyadam wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT alozairiebaa wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT stewartkurtis wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT hopkinsdavid wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT rundlejennifer wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT basudevneel wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT mohamedalizahra wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
AT ismailkhalida wearabletechnologydeliveringawebbaseddiabetespreventionprogramtopeopleathighriskoftype2diabetesrandomizedcontrolledtrial
_version_ 1721484097665105920